Literature DB >> 24972769

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia.

Thomas Prebet1, Sarah Bertoli2, Jacques Delaunay3, Arnaud Pigneux4, Eric Delabesse5, Marie Joelle Mozziconacci6, Audrey Bidet7, Christian Recher8, Norbert Vey9.   

Abstract

Entities:  

Keywords:  AML; CBF; daunorubicin intensification

Mesh：

Substances：

Year:  2014        PMID： 24972769      PMCID： PMC4181266          DOI： 10.3324/haematol.2014.109827

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.

Authors:  John A Liu Yin; Michelle A O'Brien; Robert K Hills; Sarah B Daly; Keith Wheatley; Alan K Burnett
Journal:  Blood       Date:  2012-08-08       Impact factor: 22.113

2.  Prognostic index for adult patients with acute myeloid leukemia in first relapse.

Authors:  Dimitri A Breems; Wim L J Van Putten; Peter C Huijgens; Gert J Ossenkoppele; Gregor E G Verhoef; Leo F Verdonck; Edo Vellenga; Georgine E De Greef; Emanuel Jacky; Johannes Van der Lelie; Marc A Boogaerts; Bob Löwenberg
Journal:  J Clin Oncol       Date:  2005-01-04       Impact factor: 44.544

3.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Authors:  Sylvie Castaigne; Cécile Pautas; Christine Terré; Emmanuel Raffoux; Dominique Bordessoule; Jean-Noel Bastie; Ollivier Legrand; Xavier Thomas; Pascal Turlure; Oumedaly Reman; Thierry de Revel; Lauris Gastaud; Noémie de Gunzburg; Nathalie Contentin; Estelle Henry; Jean-Pierre Marolleau; Ahmad Aljijakli; Philippe Rousselot; Pierre Fenaux; Claude Preudhomme; Sylvie Chevret; Hervé Dombret
Journal:  Lancet       Date:  2012-04-05       Impact factor: 79.321

4.  Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.

Authors:  Thomas Prebet; Anne Etienne; Raynier Devillier; Emilie Romeo; Aude Charbonnier; Evelyne D'incan; Benjamin Esterni; Christine Arnoulet; Didier Blaise; Norbert Vey
Journal:  Cancer       Date:  2010-10-18       Impact factor: 6.860

5.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

6.  Anthracycline dose intensification in acute myeloid leukemia.

Authors:  Hugo F Fernandez; Zhuoxin Sun; Xiaopan Yao; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Janis Racevskis; Gordon W Dewald; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

Review 7.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

8.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

9.  Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

Authors:  John C Byrd; Amy S Ruppert; Krzysztof Mrózek; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Judith Stamberg; Prasad R K Koduru; Joseph O Moore; Robert J Mayer; Frederick R Davey; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

10.  Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.

Authors:  Thomas Prébet; Nicolas Boissel; Sarah Reutenauer; Xavier Thomas; Jacques Delaunay; Jean-Yves Cahn; Arnaud Pigneux; Bruno Quesnel; Francis Witz; Sylvain Thépot; Valérie Ugo; Christine Terre; Christian Recher; Emmanuelle Tavernier; Mathilde Hunault; Benjamin Esterni; Sylvie Castaigne; François Guilhot; Hervé Dombret; Norbert Vey
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
View more
  12 in total

Review 1.  What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?

Authors:  Priyanka Pophali; Mark Litzow
Journal:  Curr Treat Options Oncol       Date:  2017-01

Review 2.  Minimal residual disease in acute myeloid leukemia--current status and future perspectives.

Authors:  Sabine Kayser; Roland B Walter; Wendy Stock; Richard F Schlenk
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

Review 3.  Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.

Authors:  Roland B Walter; Yishai Ofran; Agnieszka Wierzbowska; Farhad Ravandi; Christopher S Hourigan; Lok Lam Ngai; Adriano Venditti; Francesco Buccisano; Gert J Ossenkoppele; Gail J Roboz
Journal:  Leukemia       Date:  2021-03-23       Impact factor: 11.528

Review 4.  MRD in AML: does it already guide therapy decision-making?

Authors:  Gert Ossenkoppele; Gerrit Jan Schuurhuis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemia.

Authors:  Alec W Stranahan; Iryna Berezniuk; Sohini Chakraborty; Faye Feller; Mona Khalaj; Christopher Y Park
Journal:  Leukemia       Date:  2022-04-23       Impact factor: 12.883

Review 6.  Clinical implications of molecular markers in acute myeloid leukemia.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Eur J Haematol       Date:  2018-10-23       Impact factor: 2.997

7.  2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.

Authors:  Michael Heuser; Sylvie D Freeman; Gert J Ossenkoppele; Francesco Buccisano; Christopher S Hourigan; Lok Lam Ngai; Jesse M Tettero; Costa Bachas; Constance Baer; Marie-Christine Béné; Veit Bücklein; Anna Czyz; Barbara Denys; Richard Dillon; Michaela Feuring-Buske; Monica L Guzman; Torsten Haferlach; Lina Han; Julia K Herzig; Jeffrey L Jorgensen; Wolfgang Kern; Marina Y Konopleva; Francis Lacombe; Marta Libura; Agata Majchrzak; Luca Maurillo; Yishai Ofran; Jan Philippe; Adriana Plesa; Claude Preudhomme; Farhad Ravandi; Christophe Roumier; Marion Subklewe; Felicitas Thol; Arjan A van de Loosdrecht; Bert A van der Reijden; Adriano Venditti; Agnieszka Wierzbowska; Peter J M Valk; Brent L Wood; Roland B Walter; Christian Thiede; Konstanze Döhner; Gail J Roboz; Jacqueline Cloos
Journal:  Blood       Date:  2021-12-30       Impact factor: 22.113

Review 8.  Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies.

Authors:  Barbara Buldini; Margarita Maurer-Granofszky; Elena Varotto; Michael N Dworzak
Journal:  Front Pediatr       Date:  2019-10-11       Impact factor: 3.418

9.  Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.

Authors:  Guido Marcucci; Susan Geyer; Kristina Laumann; Weiqiang Zhao; Donna Bucci; Geoffrey L Uy; William Blum; Ann-Kathrin Eisfeld; Timothy S Pardee; Eunice S Wang; Wendy Stock; Jonathan E Kolitz; Jessica Kohlschmidt; Krzysztof Mrózek; Clara D Bloomfield; Richard M Stone; Richard A Larson
Journal:  Blood Adv       Date:  2020-02-25

Review 10.  Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Authors:  Gerrit J Schuurhuis; Michael Heuser; Sylvie Freeman; Marie-Christine Béné; Francesco Buccisano; Jacqueline Cloos; David Grimwade; Torsten Haferlach; Robert K Hills; Christopher S Hourigan; Jeffrey L Jorgensen; Wolfgang Kern; Francis Lacombe; Luca Maurillo; Claude Preudhomme; Bert A van der Reijden; Christian Thiede; Adriano Venditti; Paresh Vyas; Brent L Wood; Roland B Walter; Konstanze Döhner; Gail J Roboz; Gert J Ossenkoppele
Journal:  Blood       Date:  2018-01-12       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.